DUBLIN--(BUSINESS WIRE)--The "Palmar Hyperhidrosis Market Insights, Epidemiology, and Market Forecast - 2030 (US)" drug pipelines has been added to ResearchAndMarkets.com's offering.
The Palmar Hyperhidrosis market report provides analysis regarding current treatment practices, an emerging drug, like Dexmecamylamine (Atacama Therapeutics), Qbrexza (Dermira Inc), potential therapies, market share of the individual therapies, historical, current and forecasted Palmar Hyperhidrosis market size from 2017 to 2030 for the United States.
The report also covers current Palmar Hyperhidrosis treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Palmar Hyperhidrosis Epidemiology
The Palmar Hyperhidrosis epidemiology chapters provide insights about historical and current Palmar Hyperhidrosis patient pool and forecasted trends for US. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. Palmar Hyperhidrosis Palmar Hyperhidrosis epidemiology is segmented by Diagnosed Prevalent Cases of Palmar Hyperhidrosis, Diagnosed cases of Palmar Hyperhidrosis, cases of Palmar Hyperhidrosis by Age, and Severe cases of Palmar Hyperhidrosis. The report includes a thorough analysis of all segmentations.
In the US, the cases of Hyperhidrosis were 15,634,521 in 2017. Moreover, the total diagnosed prevalent cases of Palmar Hyperhidrosis in the United States were found to be 1,407,107 in 2017.
According to the publisher's analysis, In the United States, the highest number of Palmar Hyperhidrosis was reported to be among individuals above 18 years of age.
In the United States, out of all the total prevalent cases reported 773,909 severe and 633,198 non-severe cases for Palmar Hyperhidrosis in 2017.
Palmar Hyperhidrosis Drug Chapters
The drug chapter segment of the Palmar Hyperhidrosis report encloses the detailed analysis of the Palmar Hyperhidrosis pipeline drug. It also helps understand the Palmar Hyperhidrosis clinical trial details, expressive pharmacological action, agreements of the included drug, and the latest news and press releases.
Treatment is focused entirely on managing symptoms and supporting the health and well-being of the affected child or adult. The management of Palmar Hyperhidrosis revolves around the appropriate therapies for the physical and neurological problems encountered in the condition and provision for the special educational needs, given the precise cognitive profiles and behavioral features of the condition. There are many upcoming mono and combinational therapies such as Dexmecamylamine (Atacama Therapeutics), Qbrexza (Dermira Inc), etc. for the treatment of Palmar Hyperhidrosis in the pipeline.
Palmar Hyperhidrosis Market Outlook
The Palmar Hyperhidrosis market size is expected to increase at a significant CAGR during the study period (2017-2030). The United States accounts for the Palmar Hyperhidrosis market size, with USD 246.1 million in 2017.
Palmar Hyperhidrosis Drugs Uptake
This section focusses on the rate of uptake of the potential drugs in the Palmar Hyperhidrosis market that are expected to get launched in the market during the study period 2017-2030. The analysis covers Palmar Hyperhidrosis market uptake by drugs, patient uptake by therapies, and sale of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and comparison of the drugs based on market share and size, which will again be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The dynamics of the Palmar Hyperhidrosis market is anticipated to experience a positive shift in the coming years owing to the expected launch of emerging therapies.
Palmar Hyperhidrosis Pipeline Development Activities
The report provides insights into different therapeutic candidates in Phase II and Phase III stage. It also analyses Palmar Hyperhidrosis key players involved in developing targeted therapeutics.
Pipeline Development Activities
The report covers the detailed information of Palmar Hyperhidrosis collaborations, acquisition and merger, licensing, patent details, and other information for Palmar Hyperhidrosis emerging therapies.
Reimbursement Scenario in Palmar Hyperhidrosis
Approaching reimbursement, proactively, can have a positive impact both during the late stages of product development and well after product launch. In a report, the publisher considers reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.
Key Topics Covered:
1. Key Insights
2. Executive Summary of Palmar Hyperhidrosis
3. SWOT Analysis for Palmar Hyperhidrosis
4. Disease Background and Overview
4.1. Introduction
4.2. Symptoms
4.3. Pathophysiology
4.4. Evidence of genetic transmission
4.5. Quality of life
4.6. Diagnosis
5. Epidemiology and Patient Population
5.1. Key Findings
5.2. Assumptions and Rationale - United States
5.3. The United States
5.3.1. Prevalent Cases of Hyperhidrosis in the United States
5.3.2. Diagnosed Prevalent Cases of Palmar Hyperhidrosis in the United States
5.3.3. Age-specific Cases of Palmar Hyperhidrosis in the United States
5.3.4. Severity-specific Cases of Palmar Hyperhidrosis in the United States
6. Treatment
7. Guidelines
8. Unmet Needs
9. Organizations contributing toward Palmar Hyperhidrosis
10. Case Reports
10.1. Hyperhidrosis: A Patient Case
10.2. Hyperhidrosis
11. Patient Journey
11.1. Patient Journey: General
12. Emerging Therapies
12.1. Key Competitors
12.2. Dexmecamylamine: Atacama Therapeutics
12.2.1. Product Description
12.2.2. Other Developmental Activities
12.2.3. Clinical Development
12.3. Qbrexza: Dermira, Inc.
12.3.1. Product Description
12.3.2. Other Development Activities
12.3.3. Clinical Development
13. Palmar Hyperhidrosis: Market Analysis
13.1. Key Findings
13.2. Market Outlook: The United States
13.2.1. The United States Market Size
14. Market Drivers
15. Market Barriers
16. Reimbursement
17. Appendix
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/bj7o29
